HK Stock Market Move | Biocytogen Pharmaceuticals-B(02315)rose nearly 13% after profit announcement, with estimated annual revenue growth of about 40% and net profit growth of about 400%.

Biocytogen Pharmaceuticals-B(02315) rose nearly 13% after the profit notice, rising 8.82% to 47.88 Hong Kong dollars as of the time of writing, with a turnover of 27.715 million Hong Kong dollars. In terms of news, Biocytogen Pharmaceuticals released a performance forecast for 2025, expecting to achieve annual revenue of about 1.369 billion to 1.389 billion yuan, an increase of 389 million to 408 million yuan compared to the same period last year, with a year-on-year growth rate of 39.61% to 41.65%; It is expected to achieve a net profit attributable to the parent company of about 162 million to 182 million yuan, an increase of 129 million to 149 million yuan compared to the same period last year, with a significant year-on-year increase of 384.26% to 443.88%. The announcement stated that benefiting from the continued expansion of overseas markets, combined with the recovery and warming of the domestic biopharmaceutical industry, the company's operating income achieved high-speed growth; the high barriers of technological advantages guaranteed the business gross profit maintaining at a high level, and lean management measures further promoted operational efficiency improvement, enabling the company's profit level to increase rapidly.